• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The method of obtaining 2-guanidIno-4-imchdazothiazols of the general formula (1) T in H-t-C, J. HgXHH- - H, where R is -NHj-, HHRi or NHCOR, where R, is alkyl with 1-6 carbon atoms or (CH4) Ar, where ha is 0-2, Ar is fenl or their pharmaceutically acceptable c) 1x additive salts of acids, distinguishing with. ". That the compound of the formula (I) and N i HLZ 2CH1 Pg D is subjected to interaction with the compound RCN, where R has the indicated values, at a temperature of 50, pH 4.5 with the release of the target product or, if necessary, the compound of the formula
    公开号:SU1153829A3
    申请号:SU813344744
    申请日:1981-10-13
    公开日:1985-04-30
    发明作者:Ламаттина Лоренс；Эндрю Липински Кристофер
    申请人:Пфайзер Инк (Фирма)；
    IPC主号:
    专利说明:

    I The invention relates to a process for the preparation of novel 2-guaiidino-4-imide arylthiaoles or their salts, which exhibit activity as a counter-agent for retinal agent and histone mine antagonists Nl and ij and are useful respectively for the prevention and treatment of posed gastric acidity and peptic acid. The formation reactions of the imidazole ring from aminoketes and cyanate fij are known. The purpose of the invention is the synthesis of new compounds with valuable properties. This goal is achieved by those compounds of the general formula (I) HgNCNH where R is NHj-NHR, or NHCOR, where alkyl with 1-6 carbon atoms 0-2, Ar is feyl CH, Ar), where m is NIL, or their pharmaceutically Acceptable acid addition salts are prepared by reacting the compound and form COGHiNHa TtT N-Tt NH jf J 7HG1 Hz-Nbrt s- |,, K with the compound form / yy RCII |, where K has the indicated temperature at 5 (bt, pH 4 , 5 with the introduction of the target product, if necessary, a compound of the formula (I), where R is NHj, is subjected to viral vuIludeist VIS with halonangic carboxylic acid to form compoundsin, in which R is where R is an alkyl with fb carbon atoms and the target product is split free or in salt form. Salts are obtained by contacting the free base with a suitable mineral or organic acid in a water solution or in the organic solvent. The solid salt can then be obtained by precipitation or by evaporation of the solvent. Pharmaceutically acceptable acid addition salts according to the invention include 9 hydrochloride, sulfate, bisulfate, mesylate, nitrate, phosphate, acetate, lactate, maleate, fum rat, citrate, tartrate, succinate and gluconate Preferred salts are the hydrochloride and dihydrochloride. If necessary, the compounds of formula (I) in the form of free bases can be obtained from their acid addition salts using a FITTING {B4 treatment with a base followed by freezing of the free base with an organic solvent approach. Example 1. 2-Azido-T- (2-guandino-4-thiazolyl) e tanon. 50 g (0 "14 moles.) of hydrobromous 2-bromo-1- (2-guanidino-4-thiazolyl) 9thanone, 23.6 g of 0.36 nol) sodium azide and 250 ml of dimethylformam gian are mixed at room temperature 1, 5 h. The mixture is drunk in t, 5 l of water and the aqueous solution is alkalinized with solid carbonate “atri. The precipitate is precipitated from ice, horstically taken up with water and dried, thus giving 30.6 g of (93Z) 2-az | ado-1-Carry and 4-thiazash ethanone as a light brown crystalline solid, substance with mp. . (Rael), analytical substance can be obtained by recrystallizing ethanol from absolute ethanol. VykklenO With 32,00; H 3.13; K 43.53; S 14.24. NjOS Found: C 32.22-, H 3.43; S 41.93 S 13.97. Example 2, 2-Amino-1- (2-guanidino-4-thiazolyl) ethanone dihydrochloride. A mixture of t2.0 g (53 ml) 2-azido-1- (2-guanium ino-4-thiazolyl) ethanone, 1.0; g 10% -nog palladium on carbon, too ml of ethanol, 50 ml of water and 20 ml Concentrated hydrochloric acid is hydrogenated at 3 atm at room temperature for 1 hour. Another 50 ml of water and 300 mg of 10% palladium-carbon are added at this time and hydrogenation is continued at 3 atm. another 0.75 h. The mixture is diluted with 200 ml. water, filtered to remove the catalyst, and the filtrate was concentrated, leaving 13.1 g (92%) of 2-amino-1- (2-guanidino-4-thiazolyl) ethanone dihydrochloride as a white powder, mp. more. NMR (mco-dg) (5): 8.58 (b., 4H), 8.44 (s., 1H), 4.58 (b., 4H).
    Example 3. 2-Guanidino-A- (2-amino-4-imidazolyl) thiazole.
    A mixture of 43 g (0.15 mol) of 2-amino-1- (2-guanidino-4-thiazolin) ethanone dihydrochloride, 12.6 g (0.30 mol) of cyanamide and 400 ml of water was adjusted to pH 4.5 s. by adding dropwise a 20% sodium hydroxide solution. The mixture is heated at 50-60 ° C for 16 hours. The mixture is cooled, alkalinized with an aqueous solution of sodium carbonate, and a precipitate is obtained - a substance containing tar which is removed by decantation. Further addition of ethyl acetate gives 16 g of a tan solid and & The lute substance is again purified using a mixture of dimethylformamide and ethyl acetate using a procedure that gives 12 g of a tan solid. Recrystallization of this substance from a mixture of methanol and water gives analytically pure compound specified in the preparation as reddish-brown needles. T, n, 2–7 ° С (decomp.).
    Calculated: C 37.6 &, H 4.06, N 43.91; S 14.36.
    Found: C, 37.81; H 4.31, .N 43.76.
    Example 4. 2-guanidino-4- (2-H-methylamino-4-imidazosht) thiaz ol a dihydrochloride.
    A mixture of 2.0 g (7.3 mmol) of 2-a1 di-hydrochloride 2-a1 ino-1- (2-guanidine-4-thiazolyl) ethanone, 0.62 g (11 "mol) of N-methyl cyanamide and 10 ml of water is brought to pH 4.5 by adding dropwise a 20% sodium hydroxide solution. The mixture is heated at 50 ° C for 16 hours. The mixture is cooled, taken up with aq. 1 sodium carbonate solution and the resulting precipitate is collected by filtration, then washed successively with cold water, acetone and acetonitrile. The crude solid is converted to its dihydrochloride salt by dissolving it in a minimal amount of saturated methanolic hydrogen chloride solution, then ether is slowly added. Initially, a tar-smeared substance precipitates, which is removed by decanting. The additional addition of ether results in the precipitation of a crystalline solid, which is filtered and dried. Recrystallization from a mixture of methanol and ether gives 190 mg (10%) of the pure title compound. T. pl. 280 ° C NMR (DMSO-d) (S): free base, 6.86 (b., 5H), 6.77 (s, 1H); 6.45 (s., 1H), 5.60 (b., 1H) i 2.68 (d., 3N).
    Calculated: C 29.27; H 4.61; N 29.87.
    CgH ,, 2НС1
    Found: C, 30.01; H 4.81; N 29.78.
    Example 5. 2-guanidino-4- (2-H-ethylamino-4-imidazo1) thiazbl dihydrochloride.
    A mixture of 4.0 g (15 mmol) of 2-amino-1- (2-guanidino-4-thiazolyl) ztanone dihydrochloride, g (22 mmol) of H-ethylamine anamide and 20 ml of water was adjusted to pH 4.5 with n (m The solution is heated at 50 ° C for 16 hours. The mixture is cooled by basifying with sodium carbonate solution and the resulting precipitate is collected by filtration and washed successively with cold water and acetone. The crude solid is converted into it. dihydrochloride salt by dissolving it in the minimum amount of saturated ethano a solution of insoluble substances and then slowly adding ether. The resulting precipitate is collected by filtration, washed with ether and dried. Recrystallization | From a mixture of ethanol and ether gives 0.46 g (10%) of the title compound T. pl.
    NMR (ShSO-df.) (S): 8.42 (b., 3N), 7.99 t., 1H) j 7.87 (s., 1H) j 7.65 (s. 1H) j 3.43 (m, 2H); 1.19 (t., ZN).
    Calculated: C 31.58, H 4.71; N 28.65.
    CqHjjK S- 2HC1
    Found: C, 31.11; H 5.38; N27.79.
    Example 6. 2-guanidino-4- (2-Hn-propylamino-4-imidazoyl) thiazole dihydrochloride.
    A mixture of 2.0 g (7.3 mmol) of 2-amino-1- (2-guanidino-4-thiacholyl ethanone dihydrochloride), 0.92 g (11 mmol)
    The Nn-propncyanamyl and 20 ml of water are adjusted to pH 4.5 by adding dropwise a 20% sodium hydroxide solution. The mixture is heated at 50 ° C for 16 hours, then cooled, alkalinized with an aqueous solution of sodium carbonate and filtered to remove insoluble material. The filtrate is concentrated and the residue is triturated with 50 ml of ethanol and filtered to remove insoluble material. Concentration of the filtrate gives a crude solid, which is converted to its dihydrochloride salt by dissolving in a saturated ethanol solution of hydrogen chloride, filtering off some insoluble matter, and diluting the filtrate with ether. The resulting precipitate is filtered, washed with ether and dried. Recrystallization from a mixture of ethanol and ether gives 180 mg (7%) of the pure title compound. T. pl. 227229 ° C,
    NMR (DMSO-d) (P): 8.40 (6H) ,; 7.86 (s, 1H); 7.64 (s. IH); 3.40 (m, 2H); t, 62 (m, 2H); 0.09 (t, 2H).
    Calculated: C 33.71; H 5.38; N 27.52.
    CigHijN S. 2HC1 -
    Found: C, 33.75; H 5.03, N 26.41.
    Example 7. 2-guanidino-4- (2-H-iso-propylamino-4-imidazoyl) thiazole ligidrochloride.
    A mixture of 2.0 g (7.3 mmol) of 2-amino-1- (2-guanidino-4-thiazole 1) ethanone dihydrochloride, 0.92 g (11 mmol) of N-iso-propiocyanamide and 20 ml of water is brought to - pH 4.5 by adding dropwise a 20% sodium hydroxide solution. The mixture is heated at 60 ° C for 16 hours. A further 0.30 g (3.7 mmol) of N-iso-propyl cyanamide is added and the mixture is heated at 110 ° C for 3 hours. The mixture is alkalinized with an aqueous solution of sodium carbonate and filtered for (Remove insoluble material. The filtrate is concentrated and the residue is triturated with 50 ml of ethanol and filtered to remove inorganics. Concentration of the filtrate gives a crude solid, which is converted to its dihydrochloride salt by dissolving in the high-grade ethanol solution of hydrogen chloride, filtering off insoluble material dilute the filtrate with ether. The resulting precipitate is filtered, washed with ether and dried. Recrystallization from a mixture of ethanol and ether gives 0.34 g (13%) of the pure title compound. mp 138 ° C.
    NMR (DMSO-dj) (5.): 8.39 (b., 6H) -, 7.82 (s, 1H) i 7.59 (s, 1I); 3.10 See, 1H); 1.05 (d, 6H).
    Calculated: C 33.7G, H 5.38 N 27.52.
    CioHijN S. 1HC1
    Found: C, 33.71; H 5.97; N 26, 15.
    Example 8. 2-guanidino-4- (2-KH-butylamino-4-imidazoyl) thiazole ligidrochloride.
    A mixture of 2.0 g (7.3 mmol) of 2-amino-1- (2-guanidino-4-thiazoyl) ethanone dihydrochloride, 1.08 g (11 mmol) of NH-butyl cyanoamol and 20 ml of sodium hydroxide solution is heated with reflux for 60 hours, then cool, alkalinized with an aqueous solution of sodium carbonate, then concentrated. The solid residue is triturated with methanol, filtered to remove insoluble substances, and the filtrate is concentrated to give an oil. The oil is taken up in 20 ml of ethanolic hydrogen chloride solution, filtered again to remove insoluble substances, and the filtrate is diluted with ether. The resulting precipitate is collected by filtration, washed with ether, and dried in vacuo, to give 0.25 g (10%) of 2-guanidino dihydrochloride - (- (2-Mn-butsh1amino-4-imidazoyl) thiazole. M.p. 224-228 ° C. LMR (DMSO-dg), (): 8.40 (B., 6H); 7, 82 (s., LH) j 7.60 (s., IH); 3.40 (m, 2H); 1.8-1.3 (m. 4H), 0, 97 (t., MN ;.
    Example 9. 2-guanidino-4- (2-M-benzylamino-4-imidazoyl) thiazole ligidrochloride.
    A mixture of 2.0 g (7.3 mmol) of 2-amino-1- (2-guanidino-4-thiazole7) dihydrochloride ethion, 1.45 g (P mmol) of N-benzylcyanamide and 20 ml of water was adjusted to pH 4, 5 by adding dropwise a 20% sodium hydroxide solution. The mixture is heated at 60 ° C. for 16 hours. More than 0.48 g (3.7 mmol) of N-6eHjnJ JinaFT, TMH; Ta n
    the mixture is heated at 110 ° C for 20 h. The mixture is cooled to room temperature, then basified with aqueous sodium carbonate. The resulting precipitate is collected by filtration, washed with water and allowed to dry. The solid is stirred in 60 m of methanol, filtered to remove insoluble substances, and the filtrate is concentrated. The residue is taken in AO ml of an ethanolic solution of hydrogen chloride, filtered to remove a precipitate of 1.5 g (51%) of the pure target compound. T; pl. NMR (DMSO-d6) (5): 8.41 (b., 6H); 7.94 (s, 1H); 7.72 (s, 1H); 7.6-7.1 (m, 5H), 4.72 (d, 2H).
    Calculated: C, 41.58; H 4.74; N 24.25.
      2HC1.
    Found: C, 41.97; H, 5.43; N, 23.80.
    Example 10. 2-guanidino-4- (2-H-phenethylaminr-4-imndaeoyl) thiazole dihydrochloride.
    A mixture of 2.0 g (7.3 mmol) of 2-amino-1- (2-guanidino-4-thiazoyl) ethanone dihydrochloride, 1.61 g (11 mmol) of N-phenethylcyanamide and 20 ml of water is adjusted to pH 4, 5 by adding dropwise a 20% sodium hydroxide solution. The mixture is heated at 60 ° C for 16 hours. A further 0.54 g (3.7 mmol) of N-phenethypcyanamide is added and the mixture is heated at 110 ° C for 20 hours. The mixture is cooled to room temperature, then basified with aqueous sodium carbonate. The resulting precipitate is collected by filtration, washed with water and allowed to dry. The solid is stirred in 60 ml of methanol, filtered to remove insoluble substances, and the filtrate is concentrated. The residue is taken up in 40 ml of an ethanolic solution of hydrogen chloride, filtered to remove insoluble substances, and the filtrate is diluted with 200 mp of ether. The resultant precipitate is 0.62 g (20%) of the pure title compound. T. pl. 187C.
    NMR (DMSO-dft), (&): 8.48 (b., 6H 7.94 (s, 1H); 7.70 (s, 1H) i 7.38 (s, 5H); 3 , 72 m., 2H) {2.96 (t., ZN).
    Calculated: C 43.06, H 5.06; N 2.1, / h.
      2ns1 n, /)
    Found: C 42.36-, H 5, 13, N 23.30.
    Example 11.2-Human-4- (2-N-acetamido-4-idazoyl) -thiazol.
    A mixture of 1.0 g (4.5 mmol) of 2-guanid-4- (2-amino-4-imidazo1) thiazole, 0.35 g (4.5 mmol) of acetyl chloride and 10 ml of pyridine is stirred at room temperature 2.5 The floating solution above is decanted from the insoluble residue and poured into 20 "ml of water. This aqueous solution is concentrated and the crude solid residue is triturated with 4 ml of water. The resulting solid is filtered and dried to give 0.18 g (16%) of the title compound. T. pl. 151-155c.
    NMR (DMSO-dg) (8): 7.38 (s, 1H) 7.2-6.8 (b., 6H); 6.76 (s, 1H); 1.97 (s., ZN); Recrystallization from a mixture of ethanol and ether gives analytically pure product. T, pl. 159-160 ° C.
    Calculated: C 38.15; H 4.62; N 34.60.
     . H, 0
    Found: C 38.09; H 4.2 G, N 34.88
    Example 12. 2-Guanidino-4- (2-N-phenylamino-4-imidazoyl) thiazol.
    A mixture of 2.3 g (8.5 mmol) of 2-amino-1- (2-guanidino-4-thiazolyl) ethanone dihydrochloride, 2.0 g (17 mmol) of N-phenylcyanamide and 40 ml of water is heated at 50 ° C for 19h. The dark solution is filtered to remove insoluble substances and the filtrate is washed with chloroform. The aqueous filtrate is basified with a saturated solution of sodium bicarbonate and the resulting precipitate is filtered by filtration, in water, ether, then acetonitrile, to give a brown solid. This substance is dissolved in an ethanolic solution of hydrogen chloride and ether is added, resulting in precipitation of a solid. Recrystallization from the demolition of H-propanol and acetonitrile gives 479 mg of 2-guanchidino-4- (2-N-phenylamino-4-imidazolyl) thiazole dihydrochloride. T. pl. 245-247 ° C (decomp.).
    NMR (DMCO) (f): 8.2-8.0 (b., 4H) i 7.76 (s., 1H) i 7.4-7.0 (s., + B., 5H). High resolution mass spectrum, calculated for: 299.0953, found: 299.0964
    Example 13. The activity against the gastric acid inhibiting compounds of the co-lacnoe invention was determined in conscious dogs Vei denhain, which were starved during the night. Pentagastrin (Pentavlon-Ayerst) has been used to stimulate gastric acid by continuous intake into the superficial leg vein in doses previously defined as stimulating almost the maximum introduction of acid from the gastric bladder. Gastric juice was collected at intervals of 30 minutes after the start of pentagastric administration and was measured to the nearest 0.1 ml. Ten samples were taken from each dog during the experiment. The acid concentration was determined by titration with 1, O ml of Gastric juice to a pH of 7.4 using O, t, sodium hydroxide standards using an autoclave and a pH meter with a glass electrode (radiometer).
    SO minutes after the start of pentagastrin administration, a drug or vehicle was given intravenously at a dose of 1 mg / kg. The effect of inhibiting gastric acid secretion was calculated by comparing the lowest acid release after drug administration with the average value of the acid release just before the drug.
    The results showed that the compounds of examples 3-11 all inhibit the secretion of gastric acid by at least 15% at a dose of 1 mg / kg.
    Example 14. The activity of the compounds according to the invention as histamine antagonists -Hj was determined using the following procedure.
    Guinea pigs were quickly slaughtered on the head, the heart was removed and the right atrium was anatomized freely. The atrium was suspended isometrically, in a tissue bath with an adjustable temperature of 32 + 2 ° С (10 ml) containing saturated oxygen (95% 02, 5% GO) Krals-Henseleit buffer solution (pH 7.4), and they were allowed
    stabilize for approximately one hour, during which the tissue bath was flushed several times. Individual atrial contractions were monitored using a force change sensor coupled with a cardiotachometer and Crass self-cystic. After obtaining a curve showing the doses responding to histamine, a bath containing each atrium was taken out several times with fresh buffer, and the atria returned to their original values. After returning to the main HowaM in the selected final concentrations, the test compounds were added and the dose curve corresponding to histamine in the presence of an antagonist was again determined. The results showed a dose ratio of histamine concentrations required by 1X for half the maximum stimulation in the presence and absence of an antagonist, and the apparent dissociation constant for the pAg antagonist of the H receptor was determined. The results showed that the compounds of examples 3-12 have pL values greater than 5.7.
    Data confirming the activity of pA and the percentage of the antisecretory effect of the obtained compounds as compared with the known cymethidin-N-cyano-N-methyl-N-12- (5-methyl-III-imidazol-4-Il) methyl (thio) ethyl guanidine are shown in the table.
    6.3
    50 96 7.8
    111153829
    Table continuation
    12
    Table continuation
    7.0
    38 51
    9 10 6.8
    7.0
    55
    11 12 7.0
    权利要求:
    Claims (1)
    [1]
    METHOD FOR PRODUCING 2-GUANIDINO-4-IMVDA30TIA30L0V OR THEIR PHARMACEUTALLY ACCEPTABLE ADDITIVE ACID SALTS.
    (57) A method for producing 2-guanidino-4-imindazothiazoles of the general formula (I) where R is ---ΝΗ 2 ~, NHRj or NHCOR ,, where R is alkyl with 1-6 carbon atoms or (CH 4 ) m Ar, where c = 0-2, Ar is phenyl or their pharmaceutically acceptable acid addition salts, distinguishing c. i ', in that the compound of formula (II)
    NH N .COCH, N Hi
    HiNCNHA-J 2HC1 is reacted with a compound of the formula RCN ( where R has the indicated meanings, at a temperature of 50-110 ° C, pH 4.5 to isolate the desired product, or, if necessary, a compound of the formula (I), where R is KH 2 , is interaction with a carboxylic acid halide to form a compound in which R NHCOR ,, where Rj is alkyl with 1-6 carbon atoms with the release of the target product in free form or in the form of a salt.
    Priority by signs: 10/14/80 at R-NH 2 - or NHCOR ,, where R ( -alkyl with 1-6 carbon atoms or (CH z ) m Ar, where m is 0-2 Ar - phenyl. 08/20/81. R-NHR4, where R is phenyl.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1153829A3|1985-04-30|Method of obtaining 2-guanidine-4-imidazothiazoles or their pharmaceutically acceptable additive salts of acids
    KR880002232B1|1988-10-20|Preparation process for quinoline derivatives and their salts
    US4520025A|1985-05-28|Bicyclic nitrogen heterocyclic ethers and thioethers, and their pharmaceutical uses
    SU1380614A3|1988-03-07|Method of producing derivatives of aryltriazoles or hydrochloride or hydrobromic salts thereof
    CH635586A5|1983-04-15|METHOD FOR PRODUCING 1,3-DIHYDROIMIDAZO | PYRIDIN-2-ONEN.
    DE19824175A1|1999-12-02|Amino azole compounds
    HU0002952A2|2001-05-28|Benzimidazole derivatives, process for producing them, their use and pharmaceutical compositions containing them
    HU187478B|1986-01-28|Process for preparing new imidazolyl-phenyl-amidines and pharmaceutical compositions containing thereof
    EP0053767B1|1984-09-12|Tricyclic cytosine derivatives for use in pharmaceutical preparations and process for their preparation
    SU1195907A3|1985-11-30|Method of producing 2-guanidine-4-|-thiazoles or their bromide salts and method of obtaining acetylimidazole
    IE58102B1|1993-06-30|Active compounds
    DE3145678A1|1982-07-08|DIBENZAZEPINE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THE SAME
    US4649145A|1987-03-10|Thiazole derivatives
    JPH072793A|1995-01-06|Heterocyclic compound
    EP0089765A2|1983-09-28|Pyridine derivatives
    US5663350A|1997-09-02|Process for the preparation of intermediates useful for the synthesis of histamine receptor antagonists
    US3963735A|1976-06-15|Acylated 2-aminothiazole derivatives
    KR20010031297A|2001-04-16|2-Substituted 1,2-Benzisothiazole Derivatives and Their Use as Serotonin Antagonists |
    SU1217258A3|1986-03-07|Method of producing derivatives of 2-guanidine-4-heteroarylthiazol or their acid-additive salts which are acceptable in pharmacy
    KR860000103B1|1986-02-19|Process for preparing 3'-substituted-5'-|-1',2'4'-triazoles
    EP1097934B1|2004-10-13|Lk6-a derivatives
    DE2340217C2|1982-02-25|3-Benzoylthiophenes, their salts, processes for their preparation and pharmaceuticals containing these compounds
    US3835141A|1974-09-10|Quinalythiohydroximic acids and their derivatives
    US4764517A|1988-08-16|8α-|-6-n-propyl ergoline useful as a prolactin secretion inhibitor, anti-parkinson, anti-depressant agent
    US4772723A|1988-09-20|Dopamine β-hydroxylase inhibitors
    同族专利:
    公开号 | 公开日
    DD202293A5|1983-09-07|
    IE51642B1|1987-01-21|
    IL64035A|1986-01-31|
    ES515159A0|1983-06-01|
    ES8306751A1|1983-06-01|
    KR850001858B1|1985-12-28|
    YU42076B|1988-04-30|
    YU42077B|1988-04-30|
    HU186788B|1985-09-30|
    FI75821B|1988-04-29|
    YU42078B|1988-04-30|
    MY8700512A|1987-12-31|
    ES8306749A1|1983-06-01|
    FI75821C|1988-08-08|
    AR228674A1|1983-03-30|
    HU191895B|1987-04-28|
    DE3168067D1|1985-02-14|
    CS750081A2|1984-02-13|
    PL134491B1|1985-08-31|
    EP0050458B1|1985-01-02|
    DK453181A|1982-04-15|
    HK52387A|1987-07-17|
    YU105283A|1983-10-31|
    AR228675A1|1983-03-30|
    NZ198629A|1985-02-28|
    ES515158A0|1983-06-01|
    US4374843A|1983-02-22|
    PL133712B1|1985-06-29|
    PT73817B|1983-11-07|
    NO813442L|1982-04-15|
    EP0050458A3|1982-09-01|
    DD207719A5|1984-03-14|
    YU42434B|1988-08-31|
    AU548992B2|1986-01-09|
    PH18467A|1985-07-18|
    KE3707A|1987-04-03|
    IE812384L|1982-04-14|
    CA1156239A|1983-11-01|
    CS231182B2|1984-10-15|
    NO159654B|1988-10-17|
    NO159654C|1989-01-25|
    YU246481A|1983-10-31|
    ES8301978A1|1982-12-16|
    IL64035D0|1982-01-31|
    PL241644A1|1983-11-21|
    AU530589B2|1983-07-21|
    PT73817A|1981-11-01|
    YU105183A|1983-10-31|
    AR229703A1|1983-10-31|
    PH17562A|1984-10-01|
    AU3206284A|1984-11-29|
    SG23487G|1987-07-10|
    PL233430A1|1983-11-21|
    ES515157A0|1983-06-01|
    AU7628781A|1982-04-22|
    EP0050458A2|1982-04-28|
    PL241643A1|1983-11-21|
    KR830007638A|1983-11-04|
    GR75098B|1984-07-13|
    PH17856A|1985-01-09|
    ES8306750A1|1983-06-01|
    YU105383A|1983-10-31|
    AT11048T|1985-01-15|
    DD207913A5|1984-03-21|
    ES506216A0|1982-12-16|
    PL135331B1|1985-10-31|
    FI813177L|1982-04-15|
    DD207718A5|1984-03-14|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    FR1516777A|1966-08-02|1968-02-05|Innothera Lab Sa|Thiazole derivatives as well as thiazolo [4,5-d] pyridazine and their preparation|
    US3519637A|1966-12-06|1970-07-07|Hoffmann La Roche|1-nitroimidazole derivatives|
    BE758146A|1969-10-29|1971-04-28|Smith Kline French Lab|AMIDINE DERIVATIVES|
    US3950353A|1971-03-09|1976-04-13|Smith Kline & French Laboratories Limited|Pharmacologically active thiourea and urea compounds|
    HU168776B|1973-11-09|1976-07-28|
    DE2614189A1|1976-04-02|1977-10-20|Hoechst Ag|Analgesic, antiinflammatory and antipyretic thiazolyl-urea derivs. - prepd. by reacting an isocyanato-carboxylic acid cpd. with an amino-or hydrazino-thiazole|
    ZA782129B|1977-04-20|1979-03-28|Ici Ltd|Hertocyclic derivatives|
    EP0003640B1|1978-01-18|1982-01-27|Imperial Chemical Industries Plc|Antisecretory guanidine derivatives, processes for their manufacture and pharmaceutical compositions containing them|
    DE3069889D1|1979-01-18|1985-02-14|Ici Plc|Guanidine derivatives, processes for their manufacture and pharmaceutical compositions containing them|
    US4220654A|1979-06-04|1980-09-02|Merck & Co., Inc.|Cyclic imidazole cyanoguanidines|
    AU518569B2|1979-08-07|1981-10-08|Farmos-Yhtyma Oy|4-benzyl- and 4-benzoyl imidazole derivatives|US4435396A|1982-05-10|1984-03-06|Pfizer Inc.|Antiulcer 2-guanidino-4-thiazoles and process therefor|
    GB2122988B|1982-06-17|1986-06-11|Toyama Chemical Co Ltd|Process for producing 2- glyoxylic acid derivative; intermediates|
    US4482723A|1983-04-11|1984-11-13|Pfizer Inc.|Process for preparation of 4-acetyl-2-substituted-imidazoles|
    EP0156644A1|1984-04-02|1985-10-02|Pfizer Inc.|Process and intermediates for 4-acetylimidazoles|
    US4560690A|1984-04-30|1985-12-24|Pfizer Inc.|2--4-hetero-arylthiazole antiulcer agents|
    US4591595A|1984-10-11|1986-05-27|Pfizer Inc.|2-guanidino-4-thiazoles in the treatment of rheumatoid arthritis|
    US4567179A|1984-10-11|1986-01-28|Pfizer, Inc.|Antiinflammatory salts of piroxicam|
    US4632993A|1984-10-11|1986-12-30|Pfizer Inc.|Process for making 2-guanidino-4- thiazole dihydrobromide|
    WO1986003203A1|1984-11-22|1986-06-05|Yoshitomi Pharmaceutical Industries, Ltd.|Thienylthiazole derivatives|
    US4814341A|1986-08-26|1989-03-21|Reiter Lawrence A|2-guanidino-4- thiazoles as antiulcer agents|
    ES2031514T3|1986-08-29|1992-12-16|Pfizer Inc.|2-GUANIDINO-4-ARILTIAZOLES FOR THE TREATMENT OF PEPTIC ULCERS.|
    ES2054684T3|1986-10-29|1994-08-16|Pfizer|PROCEDURES FOR THE PREPARATION OF 2--4-THIAZOL AND CRYSTALLINE DIHYDROCHLORIDE OF THE SAME.|
    IL95548D0|1989-09-15|1991-06-30|Fujisawa Pharmaceutical Co|Thiazole derivatives,processes for the preparation thereof and pharmaceutical composition containing the same|
    EP0575614A1|1991-03-13|1993-12-29|Fujisawa Pharmaceutical Co., Ltd.|Thiazole derivatives|
    EP0928793B1|1998-01-02|2002-05-15|F. Hoffmann-La Roche Ag|Thiazole derivatives|
    CA2619731A1|2005-08-23|2007-03-01|Ube Industries, Ltd.|Process for preparing 1-substituted 5-acylimidazole compounds|
    WO2013146754A1|2012-03-27|2013-10-03|塩野義製薬株式会社|Aromatic heterocyclic five-membered ring derivative having trpv4 inhibitory activity|
    WO2022034121A1|2020-08-11|2022-02-17|Université De Strasbourg|H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US19623180A| true| 1980-10-14|1980-10-14|
    US06/293,574|US4374843A|1980-10-14|1981-08-20|2-Guanidino-4-heteroarylthiazoles|
    [返回顶部]